Aetna modified CPB 0841 for non-invasive measurement of advanced glycation end-products (AGEs), effective December 10, 2025. Here's what billing teams need to know.
Aetna, a CVS Health company, updated this coverage policy to explicitly classify non-invasive AGE measurement in the skin, saliva, and tears as experimental, investigational, or unproven. The Aetna AGE measurement coverage policy under CPB 0841 Aetna system applies to any Aetna member claim involving AGE testing — a category increasingly marketed to endocrinology and cardiology practices as a diabetes risk tool. No CPT or HCPCS codes for this procedure are assigned covered status under this policy. If your billing team handles claims tied to ICD-10 range E08.00–E13.9 (diabetes mellitus), this policy directly affects what you can expect to get paid.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Non-invasive Measurement of Advanced Glycation End-products |
| Policy Code | CPB 0841 |
| Change Type | Modified |
| Effective Date | December 10, 2025 |
| Impact Level | Medium — high exposure for endocrinology, diabetes care, and cardiology billing teams |
| Specialties Affected | Endocrinology, Internal Medicine, Primary Care, Cardiology, Ophthalmology |
| Key Action | Flag any claims for non-invasive AGE testing in skin, saliva, or tears as non-covered under Aetna before submitting — do not expect reimbursement |
Aetna AGE Measurement Coverage Criteria and Medical Necessity Requirements 2025
The bottom line here is simple: Aetna does not cover non-invasive measurement of advanced glycation end-products. Full stop.
Under CPB 0841, Aetna classifies AGE testing — regardless of whether it's performed on skin, saliva, or tears — as experimental, investigational, or unproven. The basis is insufficient evidence in the peer-reviewed literature. That phrase matters. It's the same language Aetna uses across multiple policy bulletins when it wants to signal that no amount of prior authorization requests will change the outcome.
The Aetna AGE measurement coverage policy applies broadly to any non-invasive method used to measure AGE accumulation. This includes the skin autofluorescence (SAF) scanning approach that device manufacturers have been actively promoting to diabetes care practices. If a patient has a diabetes mellitus diagnosis in the E08.00–E13.9 range — which is the only ICD-10 code group this policy references — and your provider orders a non-invasive AGE test, you're looking at a claim denial.
Medical necessity is not the issue here in the way billing teams typically think about it. You won't fix this with better documentation. Aetna's position is that the clinical evidence base doesn't support coverage, period. No documentation of medical necessity will override an experimental designation in a payer's coverage policy.
There's no prior authorization pathway listed in this policy. That's not an oversight — it means Aetna isn't offering a PA route to coverage. Requesting prior authorization for a service Aetna calls experimental is not a workaround. It's a waste of your team's time and your patient's expectations.
Aetna AGE Measurement Exclusions and Non-Covered Indications
This policy is, at its core, an exclusion policy. Every indication listed is non-covered.
Aetna's position is that non-invasive AGE testing — across all three specimen types — lacks the peer-reviewed evidence to support routine clinical use. The policy does not carve out exceptions for high-risk diabetic patients, patients with advanced cardiovascular disease, or any other clinical subgroup. If a provider argues that a particular patient population has stronger evidence, Aetna's answer under CPB 0841 is still no.
The real issue here is that AGE measurement has been marketed aggressively by device companies as a non-invasive, early-warning diabetes complication tool. Practices investing in that technology — or referring patients to facilities using it — need to understand that Aetna reimbursement is off the table under this policy. Patients who want this testing will need to pay out of pocket, and you should have that conversation before services are rendered, not after a denial lands.
Related policies worth knowing: CPB 0070 (Diabetic Tests, Programs and Supplies) and CPB 0381 (Cardiovascular Disease Risk Tests). If your team is coding diabetes-adjacent diagnostics, check those policies too. An AGE test billed under a cardiovascular risk framing doesn't change the underlying experimental designation.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Non-invasive AGE measurement in skin | Not Covered — Experimental | E08.00–E13.9 | Classified as experimental due to insufficient peer-reviewed evidence |
| Non-invasive AGE measurement in saliva | Not Covered — Experimental | E08.00–E13.9 | Classified as experimental due to insufficient peer-reviewed evidence |
| Non-invasive AGE measurement in tears | Not Covered — Experimental | E08.00–E13.9 | Classified as experimental due to insufficient peer-reviewed evidence |
Aetna AGE Measurement Billing Guidelines and Action Items 2025
Given the effective date of December 10, 2025, here's what your billing team needs to do now.
| # | Action Item |
|---|---|
| 1 | Audit your charge capture for any AGE measurement services billed to Aetna. Pull claims from the past 12 months. If you've been submitting AGE tests under any code against Aetna Aetna member plans, check those for denials or pending status. Don't wait for Aetna to recoup. |
| 2 | Remove non-invasive AGE testing from any Aetna fee schedule or contracted service assumptions. If your practice or facility built reimbursement projections around AGE testing for Aetna patients, update those projections to zero. This applies to skin autofluorescence scanning and any other non-invasive AGE device your practice uses. |
| 3 | Update your patient financial counseling workflow before rendering AGE services to Aetna members. Patients with Aetna coverage who want non-invasive AGE testing must be informed — in writing — that Aetna will not cover the service. Issue an Advance Beneficiary Notice equivalent for Aetna commercial members if your practice uses ABN-style forms for non-Medicare non-covered services. |
| 4 | Flag E08.00–E13.9 diagnoses in your scheduling and intake system to trigger a benefits check for AGE services. The ICD-10 range E08.00 through E13.9 covers the full diabetes mellitus spectrum. Any Aetna patient presenting with a diabetes diagnosis who is being evaluated with AGE testing needs a pre-service coverage alert in your workflow. |
| 5 | Don't use prior authorization as a workaround. Some billing teams reflexively request PA for any gray-area service. This policy isn't gray. Aetna's experimental designation in CPB 0841 means PA won't open a coverage door. Submitting PA requests for experimental services consumes staff time without changing the outcome. Save that capacity for disputes that can move. |
| 6 | Cross-reference CPB 0070 and CPB 0381 when coding diabetic and cardiovascular diagnostics. If a provider is ordering a broad panel of diabetes-related tests, make sure the AGE component is broken out and handled separately — not bundled into a code set that might otherwise be covered. Mixing covered and non-covered services in a claim creates mess for everyone. |
If you're running a high volume of endocrinology or cardiology billing for Aetna patients and you're unsure how your current service mix interacts with CPB 0841, talk to your compliance officer before December 10, 2025. This is a clean exclusion policy, but its interaction with your existing claim patterns deserves a look.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for AGE Measurement Under CPB 0841
CPB 0841 does not list specific CPT or HCPCS codes for non-invasive AGE measurement. This matters for your AGE measurement billing workflow because it means Aetna isn't signaling a specific code set to watch — the exclusion applies to the service category regardless of how it's coded.
If your billing team has been using unlisted codes or Category III CPT codes for skin autofluorescence or other non-invasive AGE tests, those claims fall under this experimental designation. The absence of a specific CPT or HCPCS code in the policy doesn't create a loophole. Aetna's experimental designation covers the procedure, not a code.
Not Covered — Experimental Services
| Service | Coverage Status | Reason |
|---|---|---|
| Non-invasive measurement of AGEs in skin | Experimental / Not Covered | Insufficient peer-reviewed evidence per CPB 0841 |
| Non-invasive measurement of AGEs in saliva | Experimental / Not Covered | Insufficient peer-reviewed evidence per CPB 0841 |
| Non-invasive measurement of AGEs in tears | Experimental / Not Covered | Insufficient peer-reviewed evidence per CPB 0841 |
Note: CPB 0841 does not list specific CPT or HCPCS codes. The experimental designation applies to the service category.
Key ICD-10-CM Diagnosis Codes
| Code Range | Description |
|---|---|
| E08.00–E13.9 | Diabetes mellitus (full range) |
This is the only ICD-10 code group referenced in CPB 0841. It covers every diabetes mellitus subtype — drug or chemical induced, due to underlying condition, type 1, type 2, other specified, and unspecified — along with their full complication and manifestation subcodes. If your patient population skews diabetic, this range touches a significant share of your Aetna book.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.